地西他滨联合预激对骨髓增生异常综合征及急性髓系白血病患者的临床疗效分析

Clinical Efficacy of Decitabine Combined with Preexcitation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

目的:对骨髓增生异常综合征(MDS)与急性髓系白血病(AML)者实施地西他滨(DAC)联合预激方案,分析观察临床上取得的治疗效果。方法:纳入临汾市人民医院血液科进行治疗的MDS和AML患者52例,依据不同治疗方式随机分配为对照组和试验组,各组26例。对照组实施常规性DAC药物治疗,试验组在常规应用DAC基础上开展预激方案治疗,治疗后分析评估两组患者的指标水平。结果:与对照组相比,试验组生存时长延长,总生存率增加,差异有统计学意义(P<0.05)。试验组不良反应发生率明显降低,与对照组相比,差异有统计学意义(P<0.05)。治疗后试验组总缓解率升高明显,与对照组相比,差异有统计学意义(P<0.05)。结论:对MDS和AML采用DAC联合预激取得的疗效较优,值得临床推行。

Objective: To analyze the clinical effect of decitabine(DAC) combined with preexcitation in patients with myelodysplastic syndrome(MDS) and acute myeloid leukemia(AML). Methods: Fifty-two patients with MDS and AML treated in Linfen People’s Hospital were included in this study and randomly divided into control group and experimental group according to the treatment methods, with 26 cases in each group. The control group was treated with conventional DAC, and the experimental group was treated with preexcitation scheme on the basis of conventional DAC. The index levels of patients in two groups after treatment were evaluated. Results: Compared with the control group, the survival time was prolonged and the overall survival rate was increased of the experimental group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05). After treatment, the total remission rate of the experimental group increased significantly compared with the control group,and the difference was statistically significant(P<0.05). Conclusion: In the field of MDS and AML, the effect of DAC combined with preexcitation is better, which is worthy of clinical promotion.